Severity of presentation is associated with time to recovery in XXXX .

@entity1 @entity4282 @entity1184 @entity229 @entity16 @entity395 @entity479
UNASSIGNED: We present a @entity1 with @entity229 -induced @entity4282 ( @entity4282 ) and relatively acute @entity16 followed by rapid recovery after surgical decompression. @entity4282 is a @entity395 characterized by @entity1184 of epidural fat, most commonly associated with exogenous @entity479 use. To our knowledge, an analysis of the dynamics of @entity479 dose related to time to onset has never been performed, or of @entity1 presentation features with respect to @entity1 outcome. We retrospectively reviewed the literature for English language series and case reports of @entity4282 associated with @entity229 use from 1975-2013. Data were compiled for 41 @entity1 regarding the prescribed dose of @entity229 and length of treatment, as well as the severity of symptoms on the Ranawat scale, time to onset, time to recovery, and degree of recovery of @entity16 . Fisher's exact test and analysis of variance were used for comparing proportions, and p values <0.05 were considered statistically significant. We found that the mean cumulative dose of @entity229 trended towards an association with a lack of recovery (p=0.06) and may be related to rate of recovery. Prescribed @entity229 dose varied inversely with the time before onset of @entity16 , but failed to reach statistical significance. Higher severity of presenting symptoms on the Ranawat scale were found to be associated with a higher likelihood of delayed recovery (p=0.035). @entity1 with symptoms lower on the Ranawat scale more frequently experienced complete neurologic recovery, though this did not reach significance. The acuity of @entity16 was not related to the time to recovery or ultimate degree of recovery. Severity of presentation on the Ranawat scale is associated with rate of recovery and may be related to degree of recovery in @entity4282 @entity1 . Cumulative dose of @entity229 may be related to degree and rate of recovery. Prescribed dose of @entity229 may be related to time to onset of @entity16 . Acuity of @entity16 is not related to rate or degree of recovery.
